Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText.
Kick-your-searchterm to multiple Engines kick-your-query now !>
A dictionary by aggregated review articles of nephrology, medicine and the life sciences
Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

suck abstract from ncbi


10.1093/annonc/mdw444

http://scihub22266oqcxt.onion/10.1093/annonc/mdw444
suck pdf from google scholar
27771610/?report=reader!6246191!27771610
unlimited free pdf from europmc27771610    free
PDF from PMC    free
html from PMC    free

suck abstract from ncbi


Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534

Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534

Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534

Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534
pmid27771610      Ann+Oncol 2017 ; 28 (1): 121-127
Nephropedia Template TP

gab.com Text

Twit Text FOAVip

Twit Text #

English Wikipedia


  • A phase II study of tivozanib in patients with metastatic and nonresectable soft-tissue sarcomas #MMPMID27771610
  • Agulnik M; Costa RLB; Milhem M; Rademaker AW; Prunder BC; Daniels D; Rhodes BT; Humphreys C; Abbinanti S; Nye L; Cehic R; Polish A; Vintilescu C; McFarland T; Skubitz K; Robinson S; Okuno S; Van Tine BA
  • Ann Oncol 2017[Jan]; 28 (1): 121-127 PMID27771610show ga
  • BACKGROUND: Soft tissue sarcomas (STSs) overexpress vascular endothelial growth factors (VEGF) and VEGF-receptors (VEGFR) activation have been associated with tumor aggressiveness. Tivozanib is a potent small molecule tyrosine kinase inhibitor against VEGFR1-3, with activity against PDGFRalpha/beta and cKIT. The primary endpoint of this study was progression free survival (PFS) rate at 16 weeks. Secondary end points were overall survival (OS), response rate, safety and correlative studies. PATIENTS AND METHODS: A Simon two-stage phase II trial was performed using tivozanib given orally at 1.5 mg daily, 3 week on 1 week off on a 28 day cycle until disease progression or intolerable toxicity. RESULTS: Fifty-eight patients were enrolled and treated with tivozanib. Leiomyosarcoma was the most common STS histological type in our cohort (47%) and 27 patients (46%) had received at least 3 lines of therapy prior to study entry. Up to 24 patients (41%) had prior VEGF targeted therapies. Partial response and stable disease were observed in 2 (3.6%) and 30 (54.5%) patients. The 16 week PFS rate was 36.4% [95% confidence interval (CI) 23.7-49.1] and a median PFS of 3.5 months (95% CI 1.8-3). Median OS observed was 12.2 months (95% CI 8.1-16.8). The most frequent all grade toxicities were fatigue (48.3%), hypertension (43.1%), nausea (31%) and diarrhea (27.6%). The most common grade three toxicity was hypertension (22.4%). Correlative studies demonstrate no correlation between the expression of VEGFR 1, 2 or 3, PDGFRalpha/beta or FGF, and activity of tivozanib. CONCLUSION: Tivozanib was well tolerated and showed antitumor activity with a promising median PFS and PFS rate at 4 months in a heavily pretreated population of metastatic STSs. Our results support further studies to assess the clinical efficacy of tivozanib in STS. CLINICAL TRIAL NUMBER: NCT01782313.
  • |Adult[MESH]
  • |Aged[MESH]
  • |Aged, 80 and over[MESH]
  • |Antineoplastic Agents/*therapeutic use[MESH]
  • |Disease-Free Survival[MESH]
  • |Enzyme-Linked Immunosorbent Assay[MESH]
  • |Female[MESH]
  • |Humans[MESH]
  • |Immunohistochemistry[MESH]
  • |Kaplan-Meier Estimate[MESH]
  • |Male[MESH]
  • |Middle Aged[MESH]
  • |Phenylurea Compounds/*therapeutic use[MESH]
  • |Quinolines/*therapeutic use[MESH]
  • |Receptors, Vascular Endothelial Growth Factor/antagonists & inhibitors[MESH]
  • |Sarcoma/*drug therapy/mortality[MESH]
  • |Soft Tissue Neoplasms/*drug therapy/mortality[MESH]


  • DeepDyve
  • Pubget Overpricing
  • suck abstract from ncbi

    Linkout box